-
公开(公告)号：KR1020120067821A
公开(公告)日：2012-06-26
申请号：KR1020100129432
申请日：2010-12-16
Applicant: 한국식품연구원
IPC: A61K31/09 , A61K31/343 , A61K36/79 , A61P3/10
Abstract: PURPOSE: A therapeutic agent containing complex lignan for treating type 2 diabetes is provided to suppress blood glucose and to reduce insulin resistance. CONSTITUTION: A therapeutic agent for treating type 2 diabetes contains complex lignin of 3-5 weight parts of schizandrin, 2-4 weight parts of gomisin A, and 0.5-1.5 weight parts of angeloylgomisin H. The schizandrin is schizandrin A, schizandrin B, schizandrin C, or mixture thereof. The complex lignin additionally contains schizandrol, angeloylgomisin O, angeloylgomisin P, epigomisin, pregomoisin, or deoxyschizandrin lignan. A health food for treating type 2 diabetes contains the complex lignan as an active ingredient. A method for reducing blood glucose comprises a step of administering the complex lignan to a subject by oral or intravenous injection, intranasal inhalation, or intramuscular or intraperitoneal administration.
Abstract translation: 目的：提供含有用于治疗2型糖尿病的复合木素素的治疗剂，以抑制血糖和降低胰岛素抵抗。 构成：用于治疗2型糖尿病的治疗剂含有3-5份重的分裂精神分裂素，2-4重量份的戈麦西斯A和0.5-1.5重量份的前叶葡萄糖素H的复合木质素。五味子素是五味子素A，五味子甙B， 五味子三素或其混合物。 复杂的木质素还含有五味子三醇，阴离子基葡萄糖苷O，阴离子基葡聚糖P，表不列生，前假丝酵母或脱氧星星木脂素。 用于治疗2型糖尿病的保健食品含有复合木素素作为活性成分。 减少血糖的方法包括通过口服或静脉内注射，鼻内吸入或肌肉内或腹膜内给药将复合木酚素施用于受试者的步骤。
-
公开(公告)号：KR1020120061019A
公开(公告)日：2012-06-12
申请号：KR1020100109063
申请日：2010-11-04
Applicant: 한국식품연구원
IPC: A61K31/198 , A61P3/04 , A61P3/06 , A61P3/10
Abstract: PURPOSE: A pharmaceutical composition and health functional food containing selenomethionine are provided to prevent and treat obesity and lipid-related metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-related metabolic diseases contains selenomethionine as an active ingredient. The pharmaceutical composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, suppository, or sterilized injection solution. Selenomethionine suppresses differentiation of adipocyte. A health functional food contains selenomethionine as an active ingredient. The health functional food is used in the form of capsules, tablets, granules, powder, or beverage.
Abstract translation: 目的：提供含有硒代甲硫氨酸的药物组合物和保健功能食品，用于预防和治疗肥胖症和与脂质有关的代谢疾病。 构成：用于预防和治疗肥胖症和与脂质有关的代谢疾病的药物组合物含有硒代甲硫氨酸作为活性成分。 药物组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，栓剂或灭菌注射液的形式制备。 硒代甲硫氨酸抑制脂肪细胞的分化。 健康功能食品含有硒代甲硫氨酸作为活性成分。 保健功能食品以胶囊，片剂，颗粒，粉末或饮料的形式使用。
-
公开(公告)号：KR1020120057690A
公开(公告)日：2012-06-07
申请号：KR1020100077227
申请日：2010-08-11
Applicant: 호서대학교 산학협력단 , 한국식품연구원
CPC classification number: A61K36/48 , A23L11/09 , A23V2200/328 , A61K2236/331 , Y10S514/866
Abstract: PURPOSE: A health functional food for anti-diabetes and diabetes treatment containing meju extract is provided to lower blood glucose in vivo and to treat and relieve type 2 diabetes without side effect. CONSTITUTION: An anti-diabetes agent contains meju extract as active ingredient. The extract includes water extract or C1-C4 low carbon number alcohol extract. A health function al food for treating acne contains the meju extract as an active ingredient. The extract is water.
Abstract translation: 目的：提供含有菊苣提取物的抗糖尿病和糖尿病治疗的保健功能食品，用于降低体内血糖，并治疗和缓解2型糖尿病，无副作用。 构成：抗糖尿病药含有菊苣提取物作为有效成分。 提取物包括水提取物或C1-C4低碳醇提取物。 用于治疗痤疮的健康功能食物含有作为活性成分的菊粉提取物。 提取物是水。
-
公开(公告)号：KR101153332B1
公开(公告)日：2012-06-07
申请号：KR1020100057167
申请日：2010-06-16
Applicant: 한국식품연구원
Abstract: 본발명은이동통신단말기로부터셋탑박스에부착된 RFID 태그정보를수신받아해당셋탑박스에서제공하는방송정보와함께그 방송정보에관련된식품정보를이동통신단말기에제공할수 있도록한 정보제공시스템및 그의정보제공방법에관한것이다. 이를위하여본 발명은셋탑박스에부착된 RFID 태그를판독하는이동통신단말기와통신가능한정보제공시스템으로, 통신망을통해상기이동통신단말기로부터판독된 RFID 태그의태그정보를수신하는수신부; 상기태그정보에셋탑박스식별정보가존재하는지여부를판단하는판단부; 상기판단부의판단결과, 상기태그정보에셋탑박스식별정보가존재하는경우해당셋탑박스식별정보를외부의방송사에제공하고, 상기외부의방송사로부터해당셋탑박스에서제공되는방송의채널정보를수신하는방송사인터페이스부; 상기방송사인터페이스부를통해수신된채널정보를이용하여데이터베이스로부터식품정보및 방송정보를각각추출하는정보추출부; 및상기추출된식품정보및 방송정보를상기이동통신단말기에제공하는정보제공부를포함하는것을특징으로하는정보제공시스템을제공한다.
-
15.发明公开바이오케닌에이 또는 약리학적으로 허용되는 이의 염을 활성성분으로 함유하는 신생혈관생성과 관련된 질환의 치료용 조성물 无效用于治疗与包含生物素或其药学上接受的药物的血管生成相关的疾病的组合物
公开(公告)号：KR1020120029557A
公开(公告)日：2012-03-27
申请号：KR1020100091411
申请日：2010-09-17
Applicant: 한국식품연구원
IPC: A61K31/352 , A61K36/48 , A61P35/00 , A61P27/02
Abstract: PURPOSE: A composition containing biochanin A or pharmaceutically acceptable salt thereof for treating angiogenesis-associated diseases is provided to treat various diseases. CONSTITUTION: A composition for treating angiogenesis-associated diseases contains biochanin A or pharmaceutically acceptable salt thereof as an active ingredient. The angiogenesis-associated diseases are cancer, diabetetic retinopathy, rheumatic arthritis, psoriasis, inflammation, endometriosis, aging or hemandioma. A pharmaceutical composition for suppressing angiogenesis contains biochanin A or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract translation: 目的：提供含有角鲨他汀A或其药学上可接受的盐用于治疗血管生成相关疾病的组合物以治疗各种疾病。 构成：用于治疗血管生成相关疾病的组合物含有作为活性成分的角鲨他汀A或其药学上可接受的盐。 血管生成相关疾病是癌症，糖尿病性视网膜病变，风湿性关节炎，牛皮癣，炎症，子宫内膜异位症，衰老或血管瘤。 用于抑制血管发生的药物组合物含有作为活性成分的角鲨他汀A或其药学上可接受的盐。
-
Patent Agency Ranking16.发明公开
公开(公告)号：KR1020120015221A
公开(公告)日：2012-02-21
申请号：KR1020100077551
申请日：2010-08-11
Applicant: 한국식품연구원
Abstract: PURPOSE: A composition containign sesamol or pharmaceutically acceptable salt is provided to suppress angiogenesis and to treat cancer, diabetic retinopathy, rheumatic arthritis, and psoriasis. CONSTITUTION: A composition for treating angiogenesis-associated diseases contains sesemol or pharmaceutically acceptable salt thereof as an active ingredient. The angiogenesis-associated diseases are cancer, diabetic retinopaghy, rheumatic arthritis, psoriasis, inflammation, endometriosis, and hemandioma. The sesamol or pharmaceutically acceptable salt thereof is contained in 0.1-10 wt%.
Abstract translation: 目的：提供含有塞萨莫酚或药学上可接受的盐的组合物以抑制血管生成并治疗癌症，糖尿病性视网膜病变，风湿性关节炎和牛皮癣。 构成：用于治疗血管生成相关疾病的组合物含有作为有效成分的西昔莫或其药学上可接受的盐。 血管生成相关疾病是癌症，糖尿病视网膜病，风湿性关节炎，牛皮癣，炎症，子宫内膜异位症和血管瘤。 芝麻酚或其药学上可接受的盐含量为0.1-10重量％。
-
公开(公告)号：KR1020120015206A
公开(公告)日：2012-02-21
申请号：KR1020100077529
申请日：2010-08-11
Applicant: 한국식품연구원
IPC: A61K31/785 , A61K31/765 , A61K31/74 , A61P3/04
CPC classification number: A61K31/785 , A23L33/175 , A61K31/195 , A61K31/765 , Y10S514/909
Abstract: PURPOSE: A composition containing poly gamma glutamic acid for preventing and treating obesity is provided to suppress differentiation of adipocytes and to activate AMPK(5'AMP-activated protein kinase). CONSTITUTION: A composition for preventing and treating obesity contains poly gamma glutamic acid(PGA) as an active ingredient. The molecular weight of PGA is 100kDa to 15,000kDa. The composition is a pharmaceutical composition or food additive. The composition further contains pharmacologically acceptable carrier. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, external use, suppository, or sterilized injection solution.
Abstract translation: 目的：提供含有用于预防和治疗肥胖症的多聚谷氨酸的组合物，以抑制脂肪细胞的分化并激活AMPK（5'AMP激活的蛋白激酶）。 构成：用于预防和治疗肥胖症的组合物含有聚γ谷氨酸（PGA）作为活性成分。 PGA的分子量为100kDa至15,000kDa。 组合物是药物组合物或食品添加剂。 组合物还含有药理学上可接受的载体。 该组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，外用，栓剂或灭菌注射液的形式制备。
-
18.发明公开
公开(公告)号：KR1020110125940A
公开(公告)日：2011-11-22
申请号：KR1020100045593
申请日：2010-05-14
IPC: A61K36/232 , A61K31/37 , A61P3/04 , A61P3/00
CPC classification number: A61K36/232 , A61K31/216 , A61K31/235 , A61K31/366 , Y10S514/909
Abstract: PURPOSE: A composition containing derivatives synthesized from decursin for preventing or treating obesity is provided to suppress fatty acid synthesis. CONSTITUTION: A composition for preventing or treating obesity contains decursinol benzoate which is synthedized from decursin. The decursinol benzoate suppresses fatty acid synthesis by AMPK(5' adenosine monophosphate-activated protein kinase) activity. A method for synthesizing decursinol benzoate comprises: a step of performing enfleurage of dried Angelicae gigantis Radix in methanol at room temperature for seven days and filtering; a step of suspending the methanol extract in distilled water and isolating dichloromethane; and a step of freeze-drying and performing silicagel column chromatography to prepare six fraction.
Abstract translation: 目的：提供含有由前代素合成的用于预防或治疗肥胖症的衍生物的组合物以抑制脂肪酸合成。 构成：用于预防或治疗肥胖症的组合物含有由前胡素合成的去甲基苯甲酸酯。 苯酚去甲酚抑制AMPK（5'腺苷单磷酸激活蛋白激酶）活性的脂肪酸合成。 合成前酚醇苯甲酸酯的方法包括：在室温下在甲醇中进行七天的过滤干燥的当归香草， 将甲醇提取物悬浮在蒸馏水中并分离二氯甲烷的步骤; 和冷冻干燥并进行硅胶柱色谱以制备6份。
-
公开(公告)号：KR101032862B1
公开(公告)日：2011-05-06
申请号：KR1020080103817
申请日：2008-10-22
CPC classification number: C07K14/47 , C12Q1/6883 , C12Q2600/158
Abstract: The present invention relates to a micro array used to diagnose heart related diseases, comprising the MMH1 (Mus musculus Heart 1) protein, an antibody against said gene or said protein, a primer set used to diagnose heart related diseases that comprises a primer for said gene, a kit used to diagnose heart related diseases that includes said primer set, and a method for diagnosing heart related diseases of mammals using said primer set.
-
公开(公告)号：KR1020100044633A
公开(公告)日：2010-04-30
申请号：KR1020080103842
申请日：2008-10-22
CPC classification number: C07K14/47 , C12Q1/6844 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , C40B40/08 , G01N33/53
Abstract: PURPOSE: A specific gene MML3 specifically developing in liver tissue of a mouse is provided to reduce a false positive from a diagnosis research of liver related disease, and to rapidly cure symptoms of the liver related disease. CONSTITUTION: A specific gene MML3 specifically developing in liver tissue is formed with an amino acid sequence. A micro array to diagnose liver related disease includes the MML3 gene. The micro array contains an antibody for the MML3 gene. A kit to diagnose the liver related disease comprises a primer set and a reagent for RT-PCR(reverse transcriptase polymerase chain reaction). The diagnosing method of the liver related disease comprises a step of separating the total RNA from a mammal sample, a step of amplifying a target sequence by performing the RT-PCR using the primer set, and a step of detecting a result subject.
Abstract translation: 目的：提供特异性基因MML3特异性在小鼠肝组织中发育，以减少肝脏相关疾病诊断研究中的假阳性，并迅速治愈肝脏相关疾病的症状。 构成：用氨基酸序列形成特异性在肝组织发育的MML3基因。 用于诊断肝脏相关疾病的微阵列包括MML3基因。 微阵列包含MML3基因的抗体。 用于诊断肝脏相关疾病的试剂盒包括引物组和用于RT-PCR（逆转录酶聚合酶链式反应）的试剂。 肝相关疾病的诊断方法包括从哺乳动物样品中分离总RNA的步骤，通过使用引物组进行RT-PCR扩增靶序列的步骤和检测结果对象的步骤。
-
-
-
-
-
-
-
-
-
Search Results
109
records
(took 0.027 seconds)
